NCT01801436View on ClinicalTrials.gov

A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma

PHASE3CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

April 30, 2008

Study Completion Date

April 30, 2008

Conditions
Multiple Myeloma
Interventions
DRUG

Bortezomib

Bortezomib 1.3 mg per (m\^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.

Sponsors
All Listed Sponsors
lead

Johnson & Johnson Taiwan Ltd

INDUSTRY